Comparison of efficacy and safety between liposome-paclitaxel injection plus carboplatin and paclitaxel plus carboplatin as first line treatment in advanced non-small cell lung cancer.
- Author:
Hong-yu WANG
1
;
Xiang-ru ZHANG
1
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Carboplatin; administration & dosage; Carcinoma, Non-Small-Cell Lung; drug therapy; Female; Humans; Liposomes; Lung Neoplasms; drug therapy; Male; Middle Aged; Paclitaxel; administration & dosage; Treatment Outcome
- From: Acta Academiae Medicinae Sinicae 2014;36(3):305-308
- CountryChina
- Language:English
-
Abstract:
OBJECTIVETo compare the efficacy and safety between liposome-paclitaxel plus carboplatin (LPC) and paclitaxel plus carboplatin (PC) as first-line treatment for advanced non-small cell lung cancer (NSCLC).
METHODSTotally 54 chemotherapy-naive NSCLC patients were equally and randomly assigned into LPC group and PC group. Liposome-paclitaxel was injected on D1 at a dosage of 175 mg/m(2); the same dose and administration with paclitaxel injection in the PC group for a maximum of 2 cycles. The efficacy and adverse reactions after 2 cycles of chemotherapy were compared between these two groups.
RESULTSThe overall response rate (CR+PR) was 44.4% in the LPC group and 33.3% in the PC group after 2 cycles of chemotherapy respectively (P=0.577). In the LPC group and PC group, the incidences of myelodepression was 81.5% and 63.0%, respectively (P=0.080), gastrointestinal toxicity was 96.3% and 77.8% respectively (P=0.100), and allergic reactions was 0 and 11.1%, respectively (P=0.000). The median time to progression was 6 months and 5 months, respectively (P=0.420).
CONCLUSIONLPC group has the same efficacy with PC group and less adverse reactions than PC group.
